SEC Info - Cardlytics, Inc. - ‘8-K’ for 1/13/20

i false i 0001666071 0001666071 2020-01-13 2020-01-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i January 13, 2020

i CARDLYTICS, INC.

(Exact Name of Registrant as Specified in its Charter)



i Delaware	i 001-38386		i 26-3039436
(State or other jurisdiction of incorporation or organization)	(Commission File Number)		(I.R.S. Employer Identification No.)
i 675 Ponce de Leon Avenue NE, Suite 6000	i Atlanta	i Georgia	i 30308
(Address of principal executive offices, including zip code)
	i (888)	i 798-5802
(Registrant's telephone, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:



i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:



Title of each class	Trading symbol	Name of each exchange on which registered
i Common Stock	i CDLX	i The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).



Emerging growth company	i ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. i ☐

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On January 13, 2020, Cardlytics, Inc. (the “Company”) issued a press release announcing certain preliminary and unaudited results for its fourth quarter ended December 31, 2019. The Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits



Exhibit		Exhibit Description
99.1		Press release dated January 13, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



		Cardlytics, Inc.

Date:	January 13, 2020	By:	/s/ *David Evans*
			David Evans
			Chief Financial Officer (Principal Financial and Accounting Officer)

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	1/13/20
	12/31/19	10-K
		List all Filings

Cardlytics, Inc. – ‘8-K’ for 1/13/20

On: Monday, 1/13/20, at 8:06am ET · For: 1/13/20 · Accession #: 1666071-20-7 · File #: 1-38386

Previous ‘8-K’: ‘8-K’ on / for 11/21/19 · Next: ‘8-K’ on / for 3/3/20 · Latest: ‘8-K’ on / for 4/9/24

Current Report — Form 8-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference